Related Experiment Video
Updated: Jun 15, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Combination therapy with interferon and ribavirin for chronic hepatitis C infection in beta-thalassaemia major
M J Saffar1, H Saffar, A R Khalilian
1Department of Paediatric Infectious DiseasesMazandaran University of Medical Sciences, Sari, Islamic Republic of Iran. saffar@softhome.net
Abstract:
Treatment of chronic hepatitis C virus (HCV) infection in transfusion-dependent beta-thalassaemia major patients is complicated by existing hepatic siderosis and the fear of ribavirin-associated haemolysis. We evaluated the efficacy and side-effects of combination interferon-alpha (INF) and ribavirin therapy for HCV-infected thalassaemia patients. A total of 17 patients were enrolled (10 nonresponders to INF monotherapy, 7 naive to treatment, mean age 23.1 years) and they received 12 months of combination therapy. The sustained virological response rate 6 months after treatment was 58.8%. Blood transfusion requirements during treatment temporarily increased by 36.6%. Combination therapy was tolerated by, and may be useful for, HCV-infected thalassaemia major patients.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Viral Hepatitis I: Introduction
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Retrovirus Life Cycles
Inhibitors Of Virion Release
